These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 10424733)
41. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Chen Z; Koeneman KS; Corey DR Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918 [TBL] [Abstract][Full Text] [Related]
43. Might telomerase enzyme be a possible target for trans-Pt(II) complexes? Colangelo D; Ghiglia A; Viano I; Mahboobi H; Ghezzi A; Cassino C; Osella D J Inorg Biochem; 2004 Jan; 98(1):61-7. PubMed ID: 14659633 [TBL] [Abstract][Full Text] [Related]
44. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183 [TBL] [Abstract][Full Text] [Related]
45. Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents. Villa R; Folini M; Perego P; Supino R; Setti E; Daidone MG; Zunino F; Zaffaroni N Int J Oncol; 2000 May; 16(5):995-1002. PubMed ID: 10762636 [TBL] [Abstract][Full Text] [Related]
46. Riccardin D, a macrocyclic bisbibenzy, inhibits human breast cancer growth through the suppression of telomerase activity. Sun CC; Xu HM; Yuan Y; Gao ZH; Lou HX; Qu XJ Basic Clin Pharmacol Toxicol; 2014 Dec; 115(6):488-98. PubMed ID: 24836118 [TBL] [Abstract][Full Text] [Related]
47. A rapid biosensor chip assay for measuring of telomerase activity using surface plasmon resonance. Maesawa C; Inaba T; Sato H; Iijima S; Ishida K; Terashima M; Sato R; Suzuki M; Yashima A; Ogasawara S; Oikawa H; Sato N; Saito K; Masuda T Nucleic Acids Res; 2003 Jan; 31(2):E4-4. PubMed ID: 12527793 [TBL] [Abstract][Full Text] [Related]
49. Telomeres and telomerase: Pharmacological targets for new anticancer strategies? Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544 [TBL] [Abstract][Full Text] [Related]
50. Enzymatic activity of endogenous telomerase associated with intact nuclei from human leukemia CEM cells. Fletcher TM; Trevino A; Woynarowski JM Biochem Biophys Res Commun; 1999 Nov; 265(1):51-6. PubMed ID: 10548489 [TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin. Gan Y; Lu J; Yeung BZ; Cottage CT; Wientjes MG; Au JL AAPS J; 2015 Jan; 17(1):268-76. PubMed ID: 25425294 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of telomerase activity in endometrial cancer cells by selenium-cisplatin conjugate despite suppression of its DNA-damaging activity by sodium ascorbate. Błasiak J; Kadłubek M; Kowalik J; Romanowicz-Makowska H; Pertyński T Teratog Carcinog Mutagen; 2002; 22(1):73-82. PubMed ID: 11754389 [TBL] [Abstract][Full Text] [Related]
53. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. Uziel O; Beery E; Dronichev V; Samocha K; Gryaznov S; Weiss L; Slavin S; Kushnir M; Nordenberg Y; Rabinowitz C; Rinkevich B; Zehavi T; Lahav M PLoS One; 2010 Feb; 5(2):e9132. PubMed ID: 20161752 [TBL] [Abstract][Full Text] [Related]
54. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Hayakawa N; Nozawa K; Ogawa A; Kato N; Yoshida K; Akamatsu Ki; Tsuchiya M; Nagasaka A; Yoshida S Biochemistry; 1999 Aug; 38(35):11501-7. PubMed ID: 10471302 [TBL] [Abstract][Full Text] [Related]